ESR1 and breast cancer: The fact that both positive and negative ERα status exerted adverse effects on patients with BRCA1/2-related BC could be explained by the different pathways activating proliferation in ERα-positive and -negative BC cells, the estrogen responsive subgroup mostly using ERα-triggered cyclin activation, and the ERα-negative subgroup proliferating predominantly due to growth factor signaling.